@EricPFierce

Eric Palmer is part of the Fierce Bioscience team and primary editor of FiercePharmaManufacturing.

fiercepharmamanufacturing.com/
Joined January 2012
  • Tweets2.2K
  • Following63
  • Followers1.5K
I will vouch for him as well and I’ve been in news business for 35 years. With the background in print, he has the skills to do whatever you need.
Carly Helfand@CarlyHFierce2 Apr 2020
If anyone needs a policy reporter, I can totally vouch for this one, given I watch him reporting all day from across our living room and all.
1
1
It is not entirely accurate that the #FDA acted quickly. Two independent labs had established the dangers of #Zantac and #rantitine months ago but it equivocated until it did its own tests. Was it double-checking, or chagrined? fiercepharma.com/manufacturi…

Zantac, generics ordered off the market after FDA finds they're a ticking time bomb

Nearly four decades after it was approved, the FDA has ordered that heartburn drug

fiercepharma.com
Erin Fox@foxerinr1 Apr 2020
Finally!!! Most places removed this from formulary and shelves months ago. Glad to see official action on this.
1
#Roche pleads for global harmony as it supercharges production of #Actemra #COVID19 tests fiercepharma.com/manufacturi…

Roche pleads for global harmony as it supercharges production of Actemra, COVID-19 tests

China’s use of Roche's Actemra for some COVID-19 patients has put the arthritis drug in the spotlight and set it up for a surge in demand. | China’s use of Roche's Actemra for some COVID-19 patients...

fiercepharma.com
Recalls of specialized drugs like #Natpara create huge issues for patients. fiercepharma.com/manufacturi… #pharma #orphandrug

Recall of Takeda's Natpara leaves patients in health limbo

It was Thursday night when Lindsey Cowles learned Takeda Pharmaceutical was recalling all doses of her hypoparathyroidism medicine Natpara. She had taken her last dose that morning. | The recent...

fiercepharma.com
2
#Takeda 's recall of eye drug #Natpara is going to be very tricky for both patients and the company. It is warning patients that simply stopping the drug is not an option. fiercepharma.com/manufacturi… #pharma

Takeda recalls Natpara but warns patients not to abruptly stop treatment 

Takeda’s been looking for a buyer for Natpara to provide some debt relief, but it has just run into some complicating circumstances. | Takeda’s been looking for a buyer for Natpara to provide some...

fiercepharma.com
2
1
1
1
Yes, #Novartis says, it is selling some of its manufacturing in #China. takeda.com/en-us/newsroom/ne…
#Glenmark recalls creams that are either too wet or too gritty fiercepharma.com/manufacturi… They were produced in its Baddi plant, which has had warehouse heat issues in the past FDA cites Glenmark plant where warehouse temperatures exceeded 110˚F fiercepharma.com/manufacturi…

Glenmark recalls creams that are either too wet or too gritty

Glenmark Pharmaceuticals has been selling off assets to invest back into its focus areas, oncology, respiratory and dermatology. | Glenmark Pharmaceuticals has been selling off assets to invest back...

fiercepharma.com
Brian Kaspar says he didn't do anything wrong at #AveXis fiercepharma.com/pharma/oust… So what really happened the #Novartis unit? #genetherapy #Zolgensma Let us know.

Ousted AveXis CSO denies wrongdoing in Novartis data scandal, taps Elon Musk lawyer

Novartis’ AveXis has already fired its former chief scientific officer Brian Kaspar in connection with the Zolgensma data manipulation scandal. | Novartis’ AveXis has already fired its chief scient...

fiercepharma.com
I suspect many of you have realized our sites are not currently accessible. Maybe yours are not as well. There is a regional outage at Cloudflare. Cloudflare says it's working on the issue.
1
J&J reported $81.5 billion revenue in 2018, nearly as much as #AppleCard How did the reset of #pharma fare? Take a look at The top 15 pharma companies by 2018 revenue fiercepharma.com/special-rep…

The top 15 pharma companies by 2018 revenue

The pharma industry is always in flux, but the big names always turn up near the top of yearly sales rankings. This year is no different, with Johnson & Johnson, Roche, Pfizer, Novartis and Merck &...

fiercepharma.com
Eric Palmer retweeted
Daniel Guinee@dpguinee18 Mar 2019
I’ve made my picks #FierceMadness – at Somerville, NJ
3
2
Last 'rights' for #Pfizer Hospira plant delivered in #FDA warning letter. fiercepharma.com/manufacturi…

Pfizer plant that is closing gets farewell warning letter from FDA

Gone but not forgotten. | Gone but not forgotten. Last year, Pfizer stopped manufacturing and recalled products from a Hospira sterile injectables plant in India that the FDA has repeatedly critici...

fiercepharma.com
Last 'rights' for #Pfizer Hospira plant delivered in #FDA warning letter. fiercepharma.com/manufacturi… #pharma

Pfizer plant that is closing gets farewell warning letter from FDA

Gone but not forgotten. | Gone but not forgotten. Last year, Pfizer stopped manufacturing and recalled products from a Hospira sterile injectables plant in India that the FDA has repeatedly critici...

fiercepharma.com
Which #pharma manufacturer has the most to lose from patent expirations this year? Think of a Swiss drugmaker whose name begins with R and that faces an onslaught of #biosimilars fiercepharma.com/special-rep…

Top 10 drugs losing exclusivity in 2019

Pharma companies do their best to fight off patent expirations and generic competition as long as possible to protect their big moneymakers. But this year looks like the end of the line for many of...

fiercepharma.com
#FDA finds #Aurobindo sterile drug plant continues to have problems fiercepharma.com/manufacturi… #pharma

FDA finds Aurobindo sterile drug plant continues to have problems

Aurobindo pledged to resolve issues at a sterile manufacturing plant in India last year after an FDA inspection cited it for problems that could lead to contamination. | Aurobindo pledged to resolve...

fiercepharma.com
2
Hitachi gets EU cell manufacturing facilities with deal to buy Apceth Biopharma fiercepharma.com/manufacturi… #pharma #celltherapy

Hitachi gets EU cell manufacturing facilities with deal to buy Apceth Biopharma

Japan’s Hitachi, which is trying to forge a leadership position as a CDMO in regenerative and cell therapies, already has facilities in the U.S. Now it is making a move into Europe. | Japan’s...

fiercepharma.com
On Friday, EMA staff lowered the 28 flags of EU member states that fly outside the agency’s offices: fiercebiotech.com/biotech/em…

EMA staff lower flags at London office as Amsterdam move nears

Staff at the European Medicines Agency have lowered the flags outside their London offices as they prepare to move to Amsterdam | Staff at the European Medicines Agency have lowered the flags outside...

fiercebiotech.com
1
1
Although the current flu vaccine has so far proven more effective than last year’s version, the threat from the virus is still evident. fiercebiotech.com/research/p…

Preventing flu with an antibody-plus-Tamiflu universal vaccine

The problem with the influenza virus is it can rapidly mutate into strains that are resistant to the yearly vaccine. That has made the search for a universal vaccine all the more challenging. | The...

fiercebiotech.com
1
4
anyone else see this from AstraZeneca? or others? It's not listing prices, but it's kind of a step toward talking about prices... in ads... HT @anitamulero fasenra.com/eosinophilic-ast…
2
2
AstraZeneca's latest value-based pact serves up Brilinta at generic-level copays: bit.ly/2HyJs16 $AZN #pharma
1
Load more